New Data and Society Guidelines Support Value of Oncotype DX Breast Recurrence Score Test in Guiding Neoadjuvant Treatment Decisions for Newly Diagnosed Patients - Seite 2

A second study² was conducted in Spain and prospectively analyzed a group of 63 patients who received neoadjuvant chemotherapy after the Oncotype DX test was performed on tumor specimens from core biopsies. The analysis also showed a strong correlation between pCR and Recurrence Score result. In particular, the Recurrence Score result was the most significant predictor of pCR when compared to other factors such as Ki67 (a classic prognostic factor), estrogen receptor status and initial tumor size. None of the patients with a Recurrence Score result of 0-25 achieved a pCR.

In the third study³, the Oncotype DX test was performed prior to surgery and patients with Recurrence Score results 0-30 received neoadjuvant endocrine therapy without chemotherapy. After four months of treatment, data from 142 patients showed that 97% of them had a clinical response or stable disease, suggesting that patients with a Recurrence Score result <31 can safely be offered neoadjuvant endocrine therapy alone with minimal risk of progression of disease.

The new data presented at ASCO20 add to existing evidence^4,5,6 and reinforce the value of the Oncotype DX test in light of recent Covid-19 pandemic recommendations.^7,8 Core biopsy specimens represent 14% of the overall Oncotype DX Breast Recurrence Score test volume, and they have a testing success rate of more than 98%.⁹

About early-stage breast cancer and the Oncotype DX test

Oncotype DX is the only genomic test validated for its ability to predict the likelihood of chemotherapy benefit as well as risk of recurrence in early-stage breast cancer. Breast cancer is the most common cancer in European women¹⁰ and affects many of them during their years dedicated to working and raising a family. While chemotherapy is routinely offered, research shows that only a minority of patients with early-stage breast cancer actually benefit from it.^11,12 The Oncotype DX test is designed to facilitate personalized clinical decisions by providing information about the biology of an individual breast cancer, with the potential to deliver financial benefits for healthcare systems.